Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials, ...

The prevalence of chronic obstructive pulmonary disease (COPD) underdiagnosis, false diagnosis, and treatment in the primary care setting is high and often inconsistent with Global Initiative for the ...

David Mannino is co-founder and chief medical officer of the COPD Foundation. He's an internal medicine doctor with a specialty in pulmonary, critical care, and sleep medicine at University of ...

An injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further treatment by 30%. The findings, published today in ...

AJMC ®: What is your role in the management of patients with chronic obstructive pulmonary disease (COPD)? Klares: As a practicing pulmonologist, my role is primarily advisory, supporting primary care ...

Verona Pharma's ensifentrine is a first-in-class, inhaled, dual inhibitor of the enzymes PDE3 and PDE4, targeting both bronchodilation and inflammation. Positive Phase 3 results from the ENHANCE ...

With climate change, a recent uptick in wildfires and smog, and increased pollution worldwide, many people are concerned about the quality of their air. In Philly, a city that continues to rank ...

Are you finding that your chronic obstructive pulmonary disease (COPD) is making it harder to do the things you enjoy? Canceling plans more often? Missing work due to flare-ups? It could mean your ...

Asthma and chronic obstructive pulmonary disease (COPD) are chronic respiratory (lung) diseases that cause breathing difficulty and coughing. Asthma affects about 28 million people in the United ...